Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial.

Autor: Soria-Utrilla V; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Malaga, Spain. Electronic address: virginiasoriau@gmail.com., Sasso CV; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Malaga, Spain. Electronic address: verosasso86@gmail.com., Romero-Zerbo SY; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Human Physiology, Faculty of Medicine, University of Malaga, Malaga, Spain; Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain. Electronic address: yaniromero@gmail.com., Adarve-Castro A; Department of Radiology, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: elaadarve@hotmail.com., López-Urdiales R; Department of Endocrinology and Nutrition, Hospital Universitario Bellvitge, Barcelona, Spain. Electronic address: rlurdiales@gmail.com., Herranz-Antolín S; Department of Endocrinology and Nutrition, Hospital Universitario de Guadalajara, Guadalajara, Spain. Electronic address: herranzantolin@yahoo.es., García-Almeida JM; Department of Endocrinology and Nutrition, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: jgarciaalmeida@yahoo.com., García-Malpartida K; Department of Endocrinology and Nutrition, Hospital Universitario Doctor Peset, Valencia, Spain; School of Health Sciences, Universidad Cardenal Herrera-CEU, CEU Universities, Castellón, Spain. Electronic address: kathe.garciamalpartida@gmail.com., Ferrer-Gómez M; Department of Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Electronic address: tofly16@gmail.com., Moreno-Borreguero A; Department of Endocrinology and Nutrition, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Electronic address: aliciamborreguero@gmail.com., Luengo-Pérez LM; Department of Endocrinology and Nutrition, Hospital Universitario de Badajoz, Badajoz, Spain. Electronic address: luismiluengo@yahoo.es., Álvarez-Hernández J; Department of Endocrinology and Nutrition, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain. Electronic address: julia.alvarez@movistar.es., Aragón-Valera C; Department of Endocrinology and Nutrition, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Electronic address: caragonva@fjd.es., Ocón-Bretón MJ; Department of Endocrinology and Nutrition, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Electronic address: mjocon@salud.aragon.es., García-Manzanares Á; Department of Endocrinology and Nutrition, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain. Electronic address: agmanzanares2010@gmail.com., Bretón-Lesmes I; Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain. Electronic address: irenebreton@gmail.com., Serrano-Aguayo P; Department of Endocrinology and Nutrition, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Electronic address: piagua@gmail.com., Pérez-Ferre N; Department of Endocrinology and Nutrition, Hospital Universitario Clínico San Carlos, Madrid, Spain. Electronic address: nataliaferre79@gmail.com., López-Gómez JJ; Department of Endocrinology and Nutrition, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. Electronic address: jjlopez161282@hotmail.com., Olivares-Alcolea J; Department of Endocrinology and Nutrition, Hospital Universitario Son Espases, Palma de Mallorca, Spain. Electronic address: jolivares@hsll.es., Moreno-Martínez M; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Jaén, Jaén, Spain. Electronic address: mmorenomtnez@gmail.com., Tejera-Pérez C; Department of Endocrinology and Nutrition, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: cristinatejera.mui@gmail.com., García-Arias S; Department of Endocrinology and Nutrition, Hospital El Bierzo, Ponferrada, León, Spain. Electronic address: sara_ga85@hotmail.com., Abad-González ÁL; Department of Endocrinology and Nutrition, Hospital General Universitario Doctor Balmis, Alicante, Spain; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Spain. Electronic address: angeluis1024@ono.com., Alhambra-Expósito MR; Department of Endocrinology and Nutrition, Hospital Universitario Reina Sofía, Córdoba, Spain; Instituto Maimónides de investigación biomédica translacional (IMIBIC), Córdoba, Spain. Electronic address: mralhambra@hotamail.com., Zugasti-Murillo A; Department of Endocrinology and Nutrition, Hospital Universitario de Navarra, Pamplona, Spain. Electronic address: azugas@hotmail.com., Parra-Barona J; Department of Endocrinology and Nutrition, Hospital de Mérida, Mérida, Spain. Electronic address: juanparrabarona@gmail.com., Torrejón-Jaramillo S; Department of Endocrinology and Nutrition, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain. Electronic address: sara.torrejon@sanitatintegral.org., Abuin J; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Malaga, Spain. Electronic address: jose.abuin.fdez@gmail.com., Fernández-García JC; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Malaga, Spain. Electronic address: jcfernandez@uma.es., Olveira G; Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, Spain; Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Malaga, Spain; Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain. Electronic address: gabolvfus@uma.es.
Jazyk: angličtina
Zdroj: Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2024 Dec 03; Vol. 44, pp. 155-164. Date of Electronic Publication: 2024 Dec 03.
DOI: 10.1016/j.clnu.2024.11.044
Abstrakt: Background and Aims: Parenteral nutrition (PN) composition could play a role in the management of systemic inflammatory response and intestinal barrier disruption. We aimed to evaluate changes in biomarkers of inflammation, oxidative status and intestinal permeability in patients with type 2 diabetes mellitus (T2DM) who received different PN lipid formulas.
Methods: This was a prospective study, including 94 patients with T2DM who received omega (n)-3 polyunsaturated fatty acids (PUFA)-enriched PN, a mixture of medium and long chain triglycerides (MCT/LCT) PN, or an olive oil-based PN. Serum levels of biomarkers of oxidative status, intestinal permeability and inflammation biomarkers were determined at day 1 and day 5 after PN initiation. Registered under ClinicalTrials.gov Identifier no. NCT02706119.
Results: At day 5 after the onset of PN, the MCT/LCT group had a significant reduction of 2 proinflammatory cytokines [interleukin (IL)-15, IL-17A], elevation of the anti-inflammatory cytokine IL-13 and increase of zonulin and indoxylsulfate. The olive oil group showed a statistically significant reduction of 5 proinflammatory cytokines [IL-1β, IL-17A, IL-6, cytokine-leukemia inhibitory factor (LIF) and tumor necrosis factor alpha (TNF-α)] and reduced concentrations of the anti-inflammatory cytokine IL-1RA, while the n-3 PUFA-enriched group presented a statistically significant reduction of 8 proinflammatory cytokines (interferon-gamma, IL-1β, IL-15, IL-17A, IL-6, LIF, monocyte chemoattractant protein 1, and TNF-α). In the between-group comparisons, indoxylsulfate significantly increased in the MCT/LCT group compared to the n-3 PUFA-enriched group, while 8-isoprostane and indoxylsulfate significantly increased in the MCT/LCT group compared to the other groups and superoxide dismutase significantly decreased in the MCT/LCT group compared to the other groups.
Conclusion: In patients with T2DM, PN lipid composition exerts a profound impact on proinflammatory, prooxidative and intestinal permeability biomarkers.
Competing Interests: Conflict of interest The authors have declared that no competing interests exist.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: